Damora Therapeutics, Inc. (DMRA)
Develops antibody drugs targeting blood cell disorders like thrombocythemia and leukemia
$29.42-0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+817.9%
The outlook
DMRA is trading near $29.42 with strong analyst backing—nine analysts average a "Strong Buy" rating, and their consensus target sits roughly 50% above the current price. The stock sits well above both its 50- and 200-day moving averages and trades in the upper three-quarters of its 52-week range, reflecting sustained upward momentum in recent months.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 9 analysts
Price trendAbove its 50- & 200-day averages
52-week range75% of the way from its 52-week low to high
Price targetAvg target +50% vs current price
Analyst price target
~12-month · 9 analysts$44.11average target+49.9% vs now
Now $29.42
Low $35.00High $51.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.81B
52-wk high
$38.33
52-wk low
$2.45
50-day avg
$25.58
200-day avg
$23.44
Trailing P/E
—